• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / CDC Releases New Guidelines for Use of Zoster Vaccine in Immunosuppressed Patients

CDC Releases New Guidelines for Use of Zoster Vaccine in Immunosuppressed Patients

August 12, 2008 By Arthritis Center

Figure: Cutaneous Zoster Outbreak
Figure: Cutaneous Zoster Outbreak

The live, attenuated vaccine Zostavax for the prevention of Herpes Zoster (Shingles) has been available for use in immunocompetent persons over the age of 60, but its use has been restricted to persons broadly labeled as immunocompromised.  This has limited the use of the effective vaccine for almost all rheumatic disease patients treated with medications, even those on medications or doses not thought to lead to substantial systemic immunosuppression.  On June 6, 2008, the Centers for Disease Control (CDC) Advisory Committee on Immunization Practices released updated directives for the appropriate use of this vaccine in such patients.

The American College of Rheumatology (ACR) has released a Hotline detailing the CDC recommendations.

The recommendations continue to discourage use of the vaccine in patients receiving biologics, those receiving high dose daily prednisone (> 20 mg per day), and those with cellular immunodeficiency (i.e. hypogammaglobulinemia).  However, consideration for giving the vaccine can be made for those receiving low dose prednisone, azathioprine, and methotrexate (< 0.4 mg/kg/week).  The ACR suggests administering the vaccine at least two weeks prior to the initiation of a biologic DMARD in those appropriate for the vaccine (i.e. age greater than 60 years).  The FDA is collecting all reports on suspected incident shingles thought to be vaccine related in these patients.  Thus, any such suspected cases should be reported to the FDA’s Medwatch passive surveillance system.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy